Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2000 1
2012 1
2013 2
2014 2
2015 4
2016 11
2017 6
2018 13
2019 7
2020 7
2021 10
2022 8
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "sbc-102"
Page 1
Sebelipase alfa: first global approval.
Shirley M. Shirley M. Drugs. 2015 Nov;75(16):1935-40. doi: 10.1007/s40265-015-0479-6. Drugs. 2015. PMID: 26452566 Review.
Sebelipase alfa (Kanuma) is a recombinant human lysosomal acid lipase (LAL) developed by Synageva BioPharma Corp. ...This article summarizes the milestones in the development of sebelipase alfa leading to this first approval for the treatment of LAL de …
Sebelipase alfa (Kanuma) is a recombinant human lysosomal acid lipase (LAL) developed by Synageva BioPharma Corp. ...This arti …
Safety of sebelipase alfa for the treatment of lysosomal acid lipase deficiency.
Ezgü F. Ezgü F. Expert Opin Drug Saf. 2022 Feb;21(2):149-155. doi: 10.1080/14740338.2022.1993186. Epub 2021 Oct 22. Expert Opin Drug Saf. 2022. PMID: 34664536 Review.
AREAS COVERED: This review mainly focuses on the safety of sebelipase alfa based on the literature including studies, case reports, and reviews up to January 2021. The search was conducted on PubMed only by using the key word "sebelipase alfa." No rest …
AREAS COVERED: This review mainly focuses on the safety of sebelipase alfa based on the literature including studies, case rep …
Sebelipase alfa: enzymatic replacement treatment for lysosomal acid lipase deficiency.
Paton DM. Paton DM. Drugs Today (Barc). 2016 May;52(5):287-93. doi: 10.1358/dot.2016.52.5.2488974. Drugs Today (Barc). 2016. PMID: 27376161 Review.
Sebelipase alfa was approved for use in 2015 for patients suffering from lysosomal acid lipase deficiency in either of its two forms. ...Important unanswered questions remain, such as to what extent treatment with sebelipase alfa alters the long-term c …
Sebelipase alfa was approved for use in 2015 for patients suffering from lysosomal acid lipase deficiency in either of its two …
Lysosomal Acid Lipase Deficiency.
Wilson DP, Patni N. Wilson DP, et al. 2023 Mar 15. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. 2023 Mar 15. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hofland J, Kalra S, Kaltsas G, Kapoor N, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, New M, Purnell J, Sahay R, Shah AS, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. PMID: 27809430 Free Books & Documents. Review.
Prior to the availability of enzyme-replacement therapy, individuals with LAL-D were treated with lipid lowering medication, liver transplant, and stem cell transplant, none of which corrected the multisystem nature of the disorder. Sebelipase alfa (Kanuma()), a rec …
Prior to the availability of enzyme-replacement therapy, individuals with LAL-D were treated with lipid lowering medication, liver transplan …
Sebelipase Alfa: A Review in Lysosomal Acid Lipase Deficiency.
Frampton JE. Frampton JE. Am J Cardiovasc Drugs. 2016 Dec;16(6):461-468. doi: 10.1007/s40256-016-0203-2. Am J Cardiovasc Drugs. 2016. PMID: 27878737 Review.
In an ongoing study in nine infants presenting with early-onset LAL-D (Wolman disease), open-label treatment with sebelipase alfa significantly improved 1-year survival compared with historical controls. ...In an ongoing study of 66 children and adults with late-ons …
In an ongoing study in nine infants presenting with early-onset LAL-D (Wolman disease), open-label treatment with sebelipase alfa …
Sebelipase alfa.
[No authors listed] [No authors listed] 2016 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2016 Mar 10. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643951 Free Books & Documents. Review.
The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency.
Erwin AL. Erwin AL. Therap Adv Gastroenterol. 2017 Jul;10(7):553-562. doi: 10.1177/1756283X17705775. Epub 2017 Apr 26. Therap Adv Gastroenterol. 2017. PMID: 28804516 Free PMC article. Review.
Sebelipase alfa is a recombinant human lysosomal acid lipase (LAL), which is administered via the intravenous route. ...Treatment of infants with the severe infantile-onset form of the disease has led to improved survival beyond the age of 1 year, and also showed im …
Sebelipase alfa is a recombinant human lysosomal acid lipase (LAL), which is administered via the intravenous route. ...Treatm …
Mepolizumab.
Cada DJ, Bindler RJ, Baker DE. Cada DJ, et al. Hosp Pharm. 2016 May;51(5):405-14. doi: 10.1310/hpj5105-405. Hosp Pharm. 2016. PMID: 27303095 Free PMC article.
The May 2016 monograph topics are sugammadex, lesinurad, selexipag, sebelipase alfa, and alectinib. The Safey MUE is on sugammadex....
The May 2016 monograph topics are sugammadex, lesinurad, selexipag, sebelipase alfa, and alectinib. The Safey MUE is on sugamm …
Pharmacoeconomic Review Report: Sebelipase Alfa (Kanuma): (Alexion Pharmaceuticals, Inc.): Indication: Indicated for the treatment of infants, children, and adults diagnosed with lysosomal acid lipase (LAL) deficiency.
[No authors listed] [No authors listed] Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Nov. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Nov. PMID: 30920785 Free Books & Documents. Review.
The manufacturer submitted a price of $8,546 per 10 mL vial of sebelipase alfa, containing 2 mg/mL concentrate solution for infusion. The average annual cost for sebelipase alfa in infantile-presentation patients ranges from $892,000 to $4.9 million pe …
The manufacturer submitted a price of $8,546 per 10 mL vial of sebelipase alfa, containing 2 mg/mL concentrate solution for in …
65 results